The Exchange had sought clarification from Cadila Healthcare with respect to news appearing in www.livemint.com on November 10, 2017 titled ‘Zydus Cadila, Intas under scanner for launching hypertension drug without permit’. The company response is enclosed.
The above information is a part of company’s filings submitted to BSE.